Skip to main content


A Massachusetts treatment organization offering multiple levels of care reports that the COVID-19 crisis is forcing some inpatients to confront difficult personal choices.
Medicare beneficiaries continue to experience limited access to evidence-based treatment for opioid use disorder, at a time when prescription opioid misuse among older adults remains a major concern.
A quality measure developed for CMS evaluates readmission rates for inpatient psychiatric facilities, but NABH president and CEO Shawn Coughlin questions whether it accurately reflects certain key factors not within the control of providers.
Even among treatment centers that espouse an abstinence approach, there is evidence of treatment's benefits in reducing harm from substance use, comprehensive outcome data from Vista Research Group suggest.
As New York advocates await final action on legislation to remove prior authorization requirements for medications to treat opioid use disorder, a new report projects major cost savings from such a move.
Back to Top